Furthermore, LB fHER2− sample groups (tumours and CLs) displayed specific upregulation of several glycolytic genes including HK1, VDAC1, and VDAC2. Similarly, LDHA—which converts pyruvate to lactic acid—was only upregulated in LB fHER2− sample groups, highlighting a particular susceptibility to glycolytic inhibitors, and the potential of the CLs described here for testing this therapeutic strategy. This evidence concerns the gene LDHA and neoplasm.